The primary pre-registration reports analyzing the efficacy and protection of OCA are noted in Table 1. In postmarketing reviews, hepatic decompensation and failure, sometimes lethal, have been noted in patients with Key biliary cholangitis with decompensated cirrhosis or Child-Pugh course B or C hepatic impairment when obeticholic acid was dosed https://johnh297ycg0.creacionblog.com/profile